کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3100534 1581651 2014 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Regular use of aspirin for cardiovascular disease prevention in Italy
ترجمه فارسی عنوان
استفاده منظم از آسپرین برای پیشگیری از بیماریهای قلبی عروقی در ایتالیا
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی طب مکمل و جایگزین
چکیده انگلیسی


• In 2013, 10.9% of Italian adults (11.2% men and 10.5% women) regularly used aspirin.
• The majority of diabetics and 40% of hypertensive individuals regularly use aspirin.
• 52% of individuals with high CVD risk do not regularly use aspirin.

ObjectiveOnly a few European studies focused on aspirin use in the general population. We provide updated information on the prevalence and determinants of regular aspirin use for the prevention of cardiovascular disease (CVD) in the Italian adult population.MethodWe used data from a survey conducted in Italy in 2013, on a sample of 3000 individuals, representative of the general Italian population aged ≥ 15 years.ResultsOverall, 10.9% of Italians reported a regular use of aspirin, 11.2% of men and 10.5% of women. Aspirin use significantly increased with age. The highest prevalence of aspirin use was observed among the elderly (30.3%), ex-smokers (22.6%), and in individuals with a diagnosis of diabetes (52.0%), hypertension (42.6%) or hypercholesterolemia (38.6%). After adjustment for several covariates, no significant heterogeneity in aspirin use was observed according to education, body mass index, and physical activity. Only 1.2% of low CVD risk individuals regularly used aspirin versus 48.3% of individuals with high CVD risk.ConclusionAbout 3.4 million high CVD risk Italians do not regularly use aspirin for primary or secondary prevention. Thus, more widespread preventive strategy is recommended for this population, once individual benefits of regular aspirin use exceed harms.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Preventive Medicine - Volume 63, June 2014, Pages 48–51
نویسندگان
, , , , , ,